Is Amneal Pharmaceuticals, Inc. (AMRX) a good stock to buy?

Olyth's institutional analysis of AMRX reveals an Altman Z-Score of 1.93 and a Piotroski F-Score of 7/9. These metrics, combined with its 5-year revenue trend ($3.02B most recent), help investors decide if AMRX fits their risk profile.

What is the current P/E ratio for AMRX?

As of the latest trading session, Amneal Pharmaceuticals, Inc. (AMRX) has a trailing P/E ratio of 53.71.

Who is the CEO of Amneal Pharmaceuticals, Inc.?

The current Chief Executive Officer of Amneal Pharmaceuticals, Inc. is Chirag K. Patel.

What was AMRX's revenue for the last 5 years?

According to its latest income statements, Amneal Pharmaceuticals, Inc. reported annual revenues of $3.02B (2025), $2.79B (2024), $2.39B (2023), $2.21B (2022), $2.09B (2021) respectively.

Does AMRX pay a dividend?

Amneal Pharmaceuticals, Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does AMRX have?

In its latest reporting period, Amneal Pharmaceuticals, Inc. generated $0.27B in Free Cash Flow against a total debt load of $2.74B.

What is the Price-to-Book (P/B) ratio of Amneal Pharmaceuticals, Inc.?

The Price-to-Book (P/B) ratio for Amneal Pharmaceuticals, Inc. (AMRX) is currently -54.67.

What is the Price-to-Sales (P/S) ratio of AMRX?

Based on trailing twelve-month data, Amneal Pharmaceuticals, Inc. (AMRX) trades at a Price-to-Sales (P/S) ratio of 1.29.

What is Amneal Pharmaceuticals, Inc.'s Return on Equity (ROE)?

Amneal Pharmaceuticals, Inc. (AMRX) has a Return on Equity (ROE) of -67.91%, representing its profitability relative to shareholder equity.

AMRX

Amneal Pharmaceuticals, Inc. · Healthcare

12.35

1.04%(-0.13)

Prev. Close

13.43

8.74%(+1.08)

Pre-market

Last Updated: — ET

52W L: $6.6852W H: $15.42

$12.26

CHG-0.89 (-6.77%)

H$13.60

L$10.00

VOL32M

AMRX (1h)

Company Profile

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

8,300

IPO Date

2018-05-07

Beta

1.32

Websitewww.amneal.com↗

AMRX

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $14.20 Average Target Price from Analysts

Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by SG Americas Securities LLC

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy

Amneal Pharmaceuticals, Inc. (AMRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

New Strong Buy Stocks for March 9th